Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr265.50 DKK
Change Today +3.00 / 1.14%
Volume 67.5K
BAVA On Other Exchanges
As of 10:59 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

bavarian nordic a/s (BAVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - kr393.00
52 Week Low
10/8/14 - kr113.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BAVARIAN NORDIC A/S (BAVA)

Related News

No related news articles were found.

bavarian nordic a/s (BAVA) Related Businessweek News

No Related Businessweek News Found

bavarian nordic a/s (BAVA) Details

Bavarian Nordic A/S, a biotechnology company, researches, develops, and manufactures novel cancer immunotherapies and vaccines for infectious diseases. The company markets IMVANEX, a non-replicating smallpox vaccine in Europe, as well as markets under the IMVAMUNE name in Canada. It is developing PROSTVAC, a targeted immunotherapy candidate for the treatment of metastatic castration-resistant prostate cancer, which is in Phase III clinical trials in collaboration with the National Cancer Institute; and CV-301, an active cancer immunotherapy product candidate, which is in Phase II clinical trials to treat colon, breast, and other cancers. The company is also involved in the development of IMVAMUNE, a non-replicating vaccine for the treatment of smallpox that is in Phase III clinical trials in the United States; and IMVAMUNE freeze-dried to treat smallpox in the liquid frozen form, which is in Phase II clinical trials. In addition, it is developing various products to treat infectious diseases that are in preclinical stage, including MVA-BN Anthrax for the treatment of anthrax in humans and animals; MVA-BN Filo vaccine for ebola and marburg; MVA-BN vaccine for selected biological threats, such as foot-and-mouth disease virus and burkholderia; and MVA-BN respiratory syncytial virus vaccine. Further, the company is involved in the development of MVA-BN Brachyury, a novel, active immunotherapy designed to induce a robust T cell immune response against Brachyury, which is in Phase I trial. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

419 Employees
Last Reported Date: 08/25/15
Founded in 1994

bavarian nordic a/s (BAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bavarian nordic a/s (BAVA) Key Developments

Bavarian Nordic A/S Receives Contract Valued at USD 9 Million from Crucell Holland B.V. as Part of Advanced Development of Prime-Boost Ebola Vaccine Regimen

Bavarian Nordic A/S announced the award of a subcontract from Crucell Holland B.V. valued at USD 9 million. This is part of a contract awarded to Janssen by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development and manufacturing of the Ebola prime-boost vaccine regimen which consists of Bavarian Nordic's MVA-BN Filo and Ad26.ZEBOV from Janssen. The five-year base subcontract covers studies to improve the manufacturing process and establish long-term storage of MVA-BN Filo bulk vaccine. The contract also includes options for an additional USD 24 million to implement process development activities for formulation of a final drug product with a longer shelf life. As part of an accelerated development program, Janssen has initiated multiple clinical studies of the prime-boost Ebola vaccine regimen in Europe and Africa. By awarding a contract to Janssen, BARDA is prioritizing the rapid development of this promising vaccine regimen candidate. To date, Bavarian Nordic has produced and delivered the bulk equivalent of over one million doses of its vaccine.

Bavarian Nordic A/S Reports Earnings Results for the Second Quarter Ended June 30, 2015; Provides Revenue Guidance for the Year 2015

Bavarian Nordic A/S reported earnings results for the second quarter ended June 30, 2015. The company has reported that net profit for the second quarter ended June 30, 2015 was DKK 61.3 million, or DKK 2.2 per share, compared to a net loss of DKK 54.9 million, or DKK 2.1 loss per share, for the same quarter ended June 30, 2014. Revenue for the second quarter ended June 30, 2015 was DKK 389.1 million, compared to DKK 164.5 million for the same quarter ended June 30, 2014. For 2015, the company expects revenue to be DKK 1.0 billion.

Bavarian Nordic A/S Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Bavarian Nordic A/S reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the six months period, the company reported revenue of DKK 623.9 million compared to DKK 450.4 million a year ago. Income before interest and taxes (EBIT) was DKK 84.8 million compared to loss before interest and taxes of DKK 69.7 million a year ago. Income before company tax was DKK 147.5 million compared to loss before company tax of DKK 63.8 million a year ago. Net profit was DKK 106.7 million or DKK 3.8 per basic share compared to net loss of DKK 53.7 million or DKK 2.1 per basic share a year ago. Cash inflow from operating activities was DKK 306.3 million compared to cash outflow from operating activities of DKK 169.5 million a year ago. Investment in intangible assets was DKK 14.2 million compared to DKK 31.0 million a year ago. Investment in property, plant and equipment was DKK 6.7 million compared to DKK 27.8 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAVA:DC kr265.50 DKK +3.00

BAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Achillion Pharmaceuticals Inc $7.38 USD -0.17
Celldex Therapeutics Inc $11.45 USD -0.41
Chimerix Inc $37.11 USD -1.39
Emergent BioSolutions Inc $28.34 USD -0.74
Valneva SE €3.22 EUR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BAVA Industry Range
Price/Earnings 38.7x
Price/Sales 5.3x
Price/Book 5.4x
Price/Cash Flow 39.4x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAVARIAN NORDIC A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at